Technological watch

Obtaining, Evaluation, and Optimization of Doxycycline-Loaded Microparticles Intended for the Local Treatment of Infectious Arthritis

Compared to the classical systemic administration, the local drug release has some advantages, such as lack of systemic toxicity and associated side effects, increased patient compliance, and a low rate of bacterial resistance. Biopolymers are widely used to design sustained drug delivery systems and biomaterials for tissue engineering. Type II collagen is the indispensable component in articular cartilage and plays a critical role in the growth and proliferation process of chondrocytes. Thus, type II collagen has drawn more attention and interest in the treatment and research of the cartilage regeneration. The aim of this study was to obtain, characterize, and optimize the microcapsules formulation based on type II collagen, sodium alginate, and sodium carboxymethyl cellulose loaded with doxycycline as an antibiotic model drug that could be incorporated further in hydrogels to improve the localized therapy of septic arthritis. The new synthesized microcapsules were assessed by spectral (FT-IR), morphological (optical microscopy), and biological analysis (enzymatic biodegradation, antimicrobial activity). The size distribution of the obtained microcapsules was determined using optical microscopy. The drug encapsulation efficiency was also determined. To optimize the microcapsules’ composition, some physical-chemical and biological analyses were subjected to an optimization technique based on experimental design, response surface methodology, and the Taguchi technique, and the adequate formulations were selected. The results obtained recommend these new microcapsules as promising drug systems to be further incorporated in type II collagen hydrogels used for septic arthritis.

Publication date: 17/10/2020

Author: Maria Minodora Marin

Reference: doi: 10.3390/coatings10100990

MDPI (coatings)


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 870292.